According to New Report, the Global Market for Apoptosis Related Products is Slated to Grow at Above 50% CAGR for the Next 5 Years

DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/reports/c85215) has announced the addition of Apoptosis 2008 to their offering.

This market insight report gives an insight into Apoptosis- Caspase Activators and Inhibitors, Protease/Proteasome Inhibitors, Bcl-2 Modulators and p53 Modulators. The study also focuses on major diseases for which the treatment is based on apoptosis comprising Cancer, Neurodegenerative Diseases, Cardiovascular Diseases and other apoptosis based diseases including HIV Infection, Organ Transplant Rejection and MODS. The study provides global market analysis for apoptosis related therapeutic products by the above apoptosis molecular pathways and also by the disease areas. Estimates and projections for the total global apoptosis related therapeutic products market are given by geographic regions encompassing United States, Europe, Japan and Rest of World. Business profiles of 41 major companies are discussed in the report. The report covers 256 companies that are engaged in apoptosis research, testing and supply of products and services. Major Contract Research Organizations and Universities serving apoptosis market are also covered in the Corporate Directory section of this report. Information related to product developments, partnerships, collaborations, and mergers and acquisitions is also included in the report. A total of 61 exhibits complement the text.

Apoptosis is considered to play a prominent and pivotal role in growth and homeostasis of metazoans. The enormous research carried out in the past few years in the field of apoptosis has led to the detection of thousands of genes that contribute and rule the phenomenon of execution, initiation, and regulation of apoptosis. The research pattern earlier was more focused towards creating a better understanding of genetic and cell biological features. Attention has now shifted towards organized biochemical and structural analysis, which has led to transparency in the study of various phenomena involved in apoptosis process. Useless cells are wiped out during growth, metamorphosis, and tissue turnover. This systematic phenomenon is termed commonly as programmed cell death or apoptosis. This phenomenon plays a central role in the operation of the immune and nervous systems. Apoptosis also plays a major role in eradicating cancerous cells.

Global market for apoptosis related products was estimated at US$ 1.5 billion in 2007 and is slated to grow at above 50% CAGR for the next 5 years. This enormous growth is mainly due to the evidence of apoptosis’ pivotal role in the mechanism of action in key disease areas including cancer, neurodegenerative and cardiovascular disorders. The growth is also owing to increasing incidences of neurodegenerative cases in major markets such as the United States and Japan. Intense research and development efforts by pharmaceutical giants such as Roche, Novartis, Sanofi-Aventis, Astra-Zeneca, Johnson & Johnson, Pfizer, Eli-Lilly, and Bristol-Myers Squibb are leading to innovative apoptosis related products (kinase kits and reagents) and drugs being introduced into the market. The intense result-oriented approaches keep the hopes of apoptosis market growth alive in the years to come. Apart from the key markets (United States and Europe), the key upcoming markets in Rest of World region include China, India, Brazil and Eastern European countries.

Companies Mentioned:

A.G. Scientific, Inc. (USA)

Abbott Laboratories (USA)

Aegera Therapeutics, Inc. (Canada)

Aida Pharmaceuticals, Inc. (China)

Alexion Pharmaceuticals, Inc. (USA)

Alfacell Corporation (USA)

Amgen, Inc. (USA)

Antisoma plc (UK)

Applied Molecular Evolution (USA)

Ariad Pharmaceuticals, Inc. (USA)

ArQule, Inc (USA)

AVI BioPharma Inc. (USA)

BD Biosciences (USA)

Cyclacel Pharmaceuticals, Inc. (USA)

Dendreon Corporation (USA)

D-Pharm Ltd. (Israel)

EntreMed, Inc. (USA)

EpiCept Corporation (USA)

F.Hoffmann-La Roche Ltd. (Switzerland)

Genta, Inc. (USA)

Genzyme Corporation (USA)

Incyte Corporation (USA)

Introgen Therapeutics, Inc. (USA)

Invitrogen, Inc. (USA)

ISIS Pharmaceuticals, Inc. (USA)

MGI Pharma, Inc. (USA)

Millennium Pharmaceuticals Inc. (USA)

Miltenyi Biotec GmbH

Novartis AG (Switzerland)

Novogen Limited (Australia)

Onyx Pharmaceuticals, Inc. (USA)

OSI Pharmaceuticals, Inc. (USA)

Pfizer, Inc. (USA)

Pharmacyclics, Inc. (USA)

Schering-Plough Corporation (USA)

Sigma-Aldrich Corporation (USA)

Takeda Pharmaceutical Co., Ltd. (Japan)

Titan Pharmaceuticals, Inc. (USA)

Vasogen, Inc. (Canada)

Vertex Pharmaceuticals, Inc. (USA)

Zentaris GmbH (Germany)

For more information visit http://www.researchandmarkets.com/reports/c85215.